Steatohepatitis

Lipocine announced positive results from its phase 2 proof of concept study that investigated LPCN 1144, an orally delivered prodrug of endogenous testosterone, in the treatment of nonalcoholic steatohepatitis, according to a press release.

The Nash-FibroTest non-invasive panel successfully diagnosed the stage of fibrosis as well as graded nonalcoholic steatohepatitis and steatosis among patients with type 2 diabetes, according to a recent study.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories in July.

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.

Using genetic markers with metabolic risk factors can predict an individual patient’s risk for developing liver related events due to non-alcoholic fatty liver disease, according to a researcher at The Liver Meeting Digital Experience.

Cannabis use correlated with a decreased prevalence and progression of steatohepatitis among patients who were obese, according to results presented at the American College of Gastroenterology Virtual Annual Meeting.

Standard of care lifestyle counseling correlated with improvements in nonalcoholic steatohepatitis or fibrosis in half of the children with nonalcoholic fatty liver, according to study results publish in Gastroenterology.

The link between two metal ion transporters and MRI based corrected Tl demonstrated a new mechanism in steatohepatitis, according to a recently published article.

Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related morbidity in patients with NAFLD, regardless of confounding factors and in patients with NASH, according to study results.